NIPH Clinical Trials Search

Basic Information

Recruitment status	completed
Health condition(s) or Problem(s) studied
Date of first enrollment	21/07/2015
Target sample size	3000
Countries of recruitment	Japan,Asia except Japan,North America,South America,Europe,Oceania
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : INN of investigational material : Tanezumab Therapeutic category code : 19- Other agents affecting nervous system and sensory organs Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : celecoxib, naproxen, diclofenac Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcome	safety efficacy
Secondary Outcome	safety efficacy

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria
Exclude criteria